Health care-related economic burden of polycystic ovary syndrome in the United States: Pregnancy-related and long-term health consequences - supplemental data

Context: Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder of reproductive-aged women, affecting approximately
5-20% of women of reproductive age. A previous estimate noted that the
economic burden of PCOS approximates $3.7 billion annually in 2020 USD
when considering only the costs of the initial diagnosis and of
reproductive endocrine morbidities, not considering the costs of
pregnancy-related and long-term morbidities. Objective: To
estimate the excess prevalence and economic burden of pregnancy-related
and long-term health morbidities attributable to PCOS. Data
Sources: PubMed, EmBase and Cochrane Library. Study
Selection: Studies in which the diagnosis of PCOS was consistent
with the Rotterdam, National Institutes of Health (NIH), or Androgen
Excess & PCOS (AE-PCOS) Society criteria, or that used electronic
medical record diagnosis codes, or diagnosis based on histopathologic
sampling were eligible for inclusion. Studies that included an outcome of
interest and a control group of non-PCOS patients who were
matched or controlled for body mass index (BMI) were
included.   Data Extraction: Two investigators
working independently extracted data on study characteristics and
outcomes.  Data Synthesis: Data was pooled using
random-effects meta-analysis. The I 2 statistic was used
to assess inter-study heterogeneity. The quality of selected
studies was assessed using the Newcastle-Ottawa Scale.
Results: The additional total healthcare-related economic burden
due to pregnancy-related and long-term morbidities associated with PCOS in
the United States is estimated to be $4.3 billion annually in 2020 USD.